NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
01/19/2024
Back to search
Official data from USPTO
ANOVA ACCELERATING CLINICAL DEVELOPMENT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
01/19/2024
Trademark type
Combined
Nice classes
9
Filing date
09/21/2017
Registration date
11/06/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/19/2024
Last transaction
01/19/2024
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
First use anywhere
04/01/2017
First use in commerce
04/01/2017
Drawing code
3
Owner type
16
Owner location
Arlington Heights, IL
Examiner
BUSH, KAREN
Law office
L80
Current location
TMEG LAW OFFICE 108
Mark description
The mark consists of design element with inter-looping red mark or symbol to the left of literal element "ANOVA" in grey beneath this is the literal element "ACCELERATING CLINICAL DEVELOPMENT" in grey.
Holders and representatives
Holders
Anova Enterprises, LLC
Anova Enterprises, LLC
Representatives
Anova Enterprises, LLC
Technical classification
Nice Classes
Class 9
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Computer software for clinical research and instructional user guides sold as a unit; Computer hardware and softwarefor use with medical patient monitoring equipmentfor receivingprocessingtransmitting and displaying data; Computer software for controlling and managing patient medical information
Publications
History of USPTO decisions and trademark events.
29 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
01/19/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/19/2024
ES8R
TEAS SECTION 8 RECEIVED
11/06/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/06/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/21/2018
PUBO
PUBLISHED FOR OPPOSITION
08/21/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/01/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/16/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/04/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/04/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/04/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/02/2018
GNRT
NON-FINAL ACTION E-MAILED
07/02/2018
CNRT
NON-FINAL ACTION WRITTEN
07/02/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/25/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/25/2018
ALIE
ASSIGNED TO LIE
06/21/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/07/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/07/2018
DOCK
ASSIGNED TO EXAMINER
04/23/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/30/2017
GNRT
NON-FINAL ACTION E-MAILED
12/30/2017
CNRT
NON-FINAL ACTION WRITTEN
12/30/2017
DOCK
ASSIGNED TO EXAMINER
12/28/2017
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/28/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/27/2017
NWAP
NEW APPLICATION ENTERED
09/25/2017
Continuous trademark protection
Get notified about every new filing that threatens ANOVA ACCELERATING CLINICAL DEVELOPMENT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.